Gastric (MALT) lymphoma is a form of non-Hodgkin lymphoma that arises from tissue that forms the lining of the stomach, the mucosa-associated lymphoid tissue (MALT). Because gastric MALT lymphoma usually is caused by Helicobacter pylori(H. pylori) bacteria, it often can be treated successfully with antibiotics.
For the minority of cases that are not associated with H. pylori infection, or those that do not respond to antibiotics, other treatment options include radiation, chemotherapy, and surgery.What's more, because gastric MALT lymphoma is such a slow-growing cancer, many people with the disease are able to forgo treatment altogether and can instead be monitored closely by their doctor.
Active Monitoring
If patients are H Pylori positive, they are always treated with antibiotics to eradicate the H Pylori infection, which can often lead to regression of the lymphoma.
If patients are H Pylori negative, or if eradication of H Pylori does not lead to regression of the lymphoma, but the lymphoma is localized to the stomach, radiation therapy is usually used.
For people with gastric MALT lymphoma whose disease is not widespread and who do not have symptoms, active monitoring, also called watch-and-wait, might be an option.
Active monitoring entails close surveillance of a disease or condition to see if it will resolve or stabilize without treatment. Doing so can be an effective way to avoid the potential side effects of treatment. For gastric MALT lymphoma, active monitoring typically involves regular endoscopies, physical exams, and lab tests.
Triple Therapy
ForH. pylori-positive gastric MALT lymphoma, the first-line treatment is a protocol called triple therapy, which involves a combination of two antibiotics to fight the infection plus a proton pump inhibitor (PPI) drug to lower the production of gastric acid in the stomach and prevent ulcers.
The antibiotics used most often are Amoxil (amoxicillin), Biaxin (clarithromycin), Sumycin (tetracycline), and Flagyl (metronidazole).
Although it may take several months for this treatment to work, this regimen is effective in about 90% of gastric MALT lymphoma cases.
Radiation
For cases of MALT lymphoma not caused by H.pylori infection or for those that don't respond to antibiotics, radiation therapy can be an effective option.
This protocol involves directing relatively low doses of external beam radiation to the tumors in the stomach. Studies show radiotherapy of gastric (MALT) lymphoma provides excellent long-term local control and survival.
Chemotherapy
Chemotherapy is used for early-stage gastric MALT lymphomas when antibiotics fail to control the disease, or when the lymphoma recurs after a period of remission.
The chemo drugs often used are a combination of four different medications that together are known by the acronym CHOP: Cytoxan (cyclophosphamide), Adriamycin (doxorubicin), Oncovin (vincristine), and prednisone. The first three of these drugs combat cancer cells in different ways and are usually are given as injections or infusions of veins on a single day.
Prednisone is a steroid that is taken in pill form for five days.
Kinase Inhibitors
Kinase inhibitors are drugs that target lymphoma cells and block kinases—proteins that cause cancer cells to grow and flourish. Two kinase inhibitors used to treat MALT non-Hodgkin lymphoma are Imbruvica (ibrutinib) and Calquence (acalabrutinib). These drugs are taken twice a day by mouth.
Monoclonal Therapy
MALT lymphoma can be treated with a monoclonal antibodycalled Rituxan (rituximab).
Rituxan targets CD20, an antigen that's associated with gastric MALT lymphoma. (Antigens are molecules that trigger the immune response.) It's given intravenously (IV) or as an injection under the skin, and it can be used alone or in combination with chemotherapy drugs.
Two other drugs sometimes used for MALT lymphoma are Adcetris (brentuximab vedotin) and Campath (alemtuzumab).
Surgery
A gastrectomy surgery can be used to treat gastric MALT lymphoma. This procedure involves removing a portion of or all of the stomach (partial gastrectomy and total gastrectomy, respectively).
Gastrectomy is rarely if ever a first-line treatment for MALT lymphoma, given the inherent risks of surgery and the fact that the disease usually can be treated without surgery. However, it may be recommended in cases in which the lymphoma is limited to a distinct area and can be safely and easily removed.
Gastrectomy: Overview
A Word From Verywell
Learning that you or someone you care for has cancer is undoubtedly scary, even when the diagnosis is a slow-growing and easily treated disease such as gastric MALT lymphoma.
Your treatment plan can include approaches like periodic tests for active monitoring of your disease or taking medications, such as antibiotics. Learning all you can about MALT lymphoma should help to alleviate many of your concerns.
18 Sources
Verywell Health uses only high-quality sources, including peer-reviewed studies, to support the facts within our articles. Read our editorial process to learn more about how we fact-check and keep our content accurate, reliable, and trustworthy.
Violeta Filip P, “Carol Davila” University of Medicine and Pharmacy, Bucharest, Department of Internal Medicine II and Gastroenterology, Emergency University Hospital, Bucharest, et al. MALT lymphoma: epidemiology, clinical diagnosis and treatment.JMedLife. 2018;11(3):187-193. doi: 10.25122/jml-2018-0035
Safavi M, Sabourian R, Foroumadi A. Treatment of Helicobacter pylori infection: Current and future insights.World Journal of Clinical Cases. 2016;4(1):5-19. doi: doi.org/10.25122/jml-2018-0035
Nam TK, Ahn JS, Choi YD, et al. The role of radiotherapy in the treatment of gastric mucosa-associated lymphoid tissue lymphoma.Cancer Res Treat. 2014;46(1):33-40. doi: 10.4143/crt.2014.46.1.33
Alsolaiman MM, Bakis G, Nazeer T, MacDermott RP, Balint JA. Five years of complete remission of gastric diffuse large B cell lymphoma after eradication of Helicobacter pylori infection.Gut. 2003;52(4):507-509. doi: 10.1136/gut.52.4.507
Rohm CL, Acree S. Gastric MALT lymphoma refractory toHelicobacter pyloriantibiotic therapy.SAGE Open Medical Case Reports. 2019;7:2050313X1986947. doi: 10.1177/2050313X19869473
Song M. Second and third line treatment options forHelicobacter pylorieradication.WJG. 2014;20(6):1517. doi:10.1177/2050313X19869473
Kim JS, Kang SH, Moon HS, Sung JK, Jeong HY. Clinical outcome of eradication therapy for gastric mucosa-associated lymphoid tissue lymphoma according toh. Pyloriinfection status.Gastroenterology Research and Practice. 2016;2016:1-7. doi: 10.1155/2016/6794848
Lim HW, Kim TH, Choi IJ, et al. Radiation therapy for gastric mucosa-associated lymphoid tissue lymphoma: dose-volumetric analysis and its clinical implications.Radiat Oncol J. 2016;34(3):193-201. doi: 10.3857/roj.2016.01865
Shimohigashi Y, Toya R, Saito T, et al. Impact of four-dimensional cone-beam computed tomography on target localization for gastric mucosa-associated lymphoid tissue lymphoma radiotherapy: reducing planning target volume.Radiat Oncol. 2021;16(1):14. doi: 10.1186/s13014-020-01734-w
Juárez-Salcedo LM, Sokol L, Chavez JC, Dalia S. Primary gastric lymphoma, epidemiology, clinical diagnosis, and treatment.Cancer Control. 2018;25(1):107327481877825. doi: 10.1177/1073274818778256
(Video) Marginal Zone B-Cell lymphoma (MALToma) | Indolent B-Cell Non-Hodgkin’s LymphomaŠkubník J, Pavlíčková VS, Ruml T, Rimpelová S. Vincristine in combination therapy of cancer: emerging trends in clinics.Biology. 2021;10(9):849. doi: https://doi.org/10.3390/biology10090849
Sato Y, Kondo M, Inagaki A, et al. Highly frequent and enhanced injection site reaction induced by peripheral venous injection of fosaprepitant in anthracycline-treated patients.J Cancer. 2014;5(5):390-397. doi: 10.7150/jca.7706
Ikeda T, Fujiwara S ichiro, Nakajima Hi, et al. Impact of prednisolone dosage in the CHOP regimen for follicular lymphoma: a retrospective study.Int J Hematol. 2020;112(3):369-376. doi: 10.1007/s12185-020-02908-8
Shah H, Stephens D, Seymour J, Maddocks K. Incorporating novel targeted and immunotherapeutic agents in the treatment of b-cell lymphomas.American Society of Clinical Oncology Educational Book. 2021;(41):310-327. doi: 10.1007/s12185-020-02908-8
Annibali O, Chiodi F, Sarlo C, et al. Rituximab as single agent in primary malt lymphoma of the ocular adnexa.BioMed Research International. 2015;2015:e895105. doi: 10.1155/2015/895105
Pierpont TM, Limper CB, Richards KL. Past, present, and future of rituximab—the world’s first oncology monoclonal antibody therapy.Front Oncol. 2018;8:163. doi: 10.3389/fonc.2018.00163
Saulite I, Guenova E, Hoetzenecker W. Adverse reactions of antibody-therapy for primary cutaneous lymphomas: rituximab, brentuximab vedotin, alemtuzumab, and mogamulizumab. In: Puig L, Gulliver W, eds.Current Problems in Dermatology. Vol 53. S. Karger AG; 2018:70-81. doi: 10.1159/000478079
Juárez-Salcedo LM, Sokol L, Chavez JC, Dalia S. Primary gastric lymphoma, epidemiology, clinical diagnosis, and treatment.Cancer Control. 2018;25(1):107327481877825. doi: 10.1177/1073274818778256
Additional Reading
American Cancer Society. Treating B-cell non-hodgkin lymphoma.
By Indranil Mallick, MD
Indranil Mallick, MD, DNB, is a radiation oncologist with a special interest in lymphoma.
See Our Editorial Process
Meet Our Medical Expert Board
Share Feedback
Was this page helpful?
Thanks for your feedback!
What is your feedback?